| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $23,422,704 | 52 | 100 |
| Courtney Phillips | GC and Corp. Secretary | 0 | $0 | 2 | $104,766 | $-104,766 |
| Sohn Catherine A. | director | 0 | $0 | 2 | $1.15M | $-1.15M |
| Bachrodt Amy | SVP, Finance | 0 | $0 | 6 | $1.33M | $-1.33M |
| Dandekar Atul | CSBO | 0 | $0 | 13 | $5.11M | $-5.11M |
| Coloma Jason V | Chief Executive Officer | 0 | $0 | 12 | $6.19M | $-6.19M |
| Bernstein Harold | President, R&D & CMO | 0 | $0 | 17 | $9.53M | $-9.53M |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also …
Over the last 12 months, insiders at Maze Therapeutics, Inc. have bought $0 and sold $23.42M worth of Maze Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Maze Therapeutics, Inc. have bought $0 and sold $11.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-29 | Sale | Dandekar Atul | CSBO | 7,500 0.0136% | $32.07 | $240,532 | -1.41% | |
| 2026-10-01 | Sale | Coloma Jason V | Chief Executive Officer | 34,501 0.0632% | $27.02 | $932,260 | +11.44% | |
| 2026-10-01 | Sale | Bernstein Harold | President, R&D & CMO | 16,141 0.0295% | $26.93 | $434,743 | +11.44% | |
| 2026-09-29 | Sale | Dandekar Atul | CSBO | 7,500 0.0136% | $27.06 | $202,921 | +2.52% | |
| 2026-09-03 | Sale | Dandekar Atul | CSBO | 3,243 0.0059% | $26.01 | $84,354 | +3.42% | |
| 2026-09-03 | Sale | Coloma Jason V | Chief Executive Officer | 11,411 0.0207% | $26.01 | $296,807 | +3.42% | |
| 2026-09-03 | Sale | Bernstein Harold | President, R&D & CMO | 5,189 0.0094% | $26.01 | $134,969 | +3.42% | |
| 2026-09-03 | Sale | Courtney Phillips | GC and Corp. Secretary | 2,012 0.0037% | $26.01 | $52,334 | +3.42% | |
| 2026-09-02 | Sale | Coloma Jason V | Chief Executive Officer | 11,227 0.0201% | $26.47 | $297,148 | -0.22% | |
| 2026-09-02 | Sale | Dandekar Atul | CSBO | 3,191 0.0057% | $26.47 | $84,457 | -0.22% | |
| 2026-09-02 | Sale | Bernstein Harold | President, R&D & CMO | 5,106 0.0091% | $26.47 | $135,142 | -0.22% | |
| 2026-09-02 | Sale | Courtney Phillips | GC and Corp. Secretary | 1,981 0.0035% | $26.47 | $52,432 | -0.22% | |
| 2026-09-01 | Sale | Coloma Jason V | Chief Executive Officer | 34,501 0.0618% | $26.29 | $906,999 | +0.60% | |
| 2026-09-01 | Sale | Bernstein Harold | President, R&D & CMO | 16,141 0.029% | $26.36 | $425,512 | +0.60% | |
| 2026-08-28 | Sale | Dandekar Atul | CSBO | 7,500 0.0128% | $27.58 | $206,824 | -2.86% | |
| 2026-08-13 | Sale | Bernstein Harold | President, R&D & CMO | 16,142 0.0291% | $27.61 | $445,621 | -1.77% | |
| 2026-08-03 | Sale | Coloma Jason V | Chief Executive Officer | 34,501 0.0626% | $26.73 | $922,315 | +0.40% | |
| 2026-07-29 | Sale | Dandekar Atul | CSBO | 7,500 0.0136% | $27.34 | $205,031 | +0.42% | |
| 2026-07-01 | Sale | Coloma Jason V | Chief Executive Officer | 34,501 0.0627% | $29.98 | $1.03M | -7.15% | |
| 2026-07-01 | Sale | Bernstein Harold | President, R&D & CMO | 14,609 0.0265% | $29.90 | $436,864 | -7.15% |
| Increased Positions | 104 | +144.44% | 10M | +25.89% |
| Decreased Positions | 27 | -37.5% | 4M | -9.98% |
| New Positions | 58 | New | 5M | New |
| Sold Out Positions | 8 | Sold Out | 412,115 | Sold Out |
| Total Postitions | 149 | +106.94% | 47M | +15.91% |